ConvaTec Group/£CTEC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ConvaTec Group
- Ticker
- £CTEC
- Sector
- Health
- Primary listing
- LSE
- Employees
- 10,000
- Headquarters
- London, United Kingdom
- Website
- www.convatecgroup.com
ConvaTec Group Metrics
BasicAdvanced
£4.8B
52.86
£0.05
0.76
£0.06
2.28%
Price and volume
Market cap
£4.8B
Beta
0.76
52-week high
£2.59
52-week low
£1.93
Average daily volume
8.3M
Dividend rate
£0.06
Financial strength
Current ratio
1.932
Quick ratio
1.064
Long term debt to equity
1.201
Total debt to equity
1.218
Dividend payout ratio (TTM)
115.32%
Interest coverage (TTM)
6.06%
Profitability
EBITDA (TTM)
434.597
Gross margin (TTM)
56.00%
Net profit margin (TTM)
4.98%
Operating margin (TTM)
16.30%
Effective tax rate (TTM)
22.50%
Revenue per employee (TTM)
£186,680
Management effectiveness
Return on assets (TTM)
6.72%
Return on equity (TTM)
7.65%
Valuation
Price to earnings (TTM)
52.859
Price to revenue (TTM)
2.603
Price to book
3.34
Price to tangible book (TTM)
-10.31
Price to free cash flow (TTM)
45.03
Free cash flow yield (TTM)
2.22%
Free cash flow per share (TTM)
0.054
Dividend yield (TTM)
2.28%
Growth
Revenue change (TTM)
5.75%
Earnings per share change (TTM)
-41.54%
3-year revenue growth (CAGR)
6.14%
10-year revenue growth (CAGR)
4.04%
3-year earnings per share growth (CAGR)
22.06%
10-year earnings per share growth (CAGR)
-7.28%
3-year dividend per share growth (CAGR)
7.05%
What the Analysts think about ConvaTec Group
Analyst ratings (Buy, Hold, Sell) for ConvaTec Group stock.
Analyst projections of the future price of ConvaTec Group stock.
Bulls say / Bears say
Underlying demand remains broad: first-half organic revenue grew 5% excluding InnovaMatrix, all four care categories contributed, and products launched in the past three years generated more than half of that growth. This suggests new products are helping the core business gain share. (Convatec)
Infusion Care is a clear growth engine: organic sales rose 7.4% in the first half, supported by demand for infusion sets in diabetes and other therapies. The company also reported progress in diversifying customers and securing its first hybrid patch-pump supply agreement. (Convatec)
Efficiency gains could lift earnings faster than sales: adjusted operating margin expanded by 460 basis points between 2021 and 2025. Management expects at least 23% in 2026 and a mid-20s margin by 2027, alongside double-digit adjusted earnings growth. (Convatec)
InnovaMatrix shows how reimbursement changes can damage product economics: US payment changes cut the product’s first-half revenue by 94%, and ConvaTec booked a $69 million impairment. Management now expects just $5–10 million of sales from it in 2026. (Convatec)
Growth has slowed and the second-half forecast demands a pick-up: underlying organic growth was 5% in the first half, down from 6.8% a year earlier. ConvaTec narrowed its full-year range to 5.5–6.5% from 5–7%, while expecting 6–8% growth in the second half. (Reuters)
Cash generation and leverage leave less room for error: first-half free cash flow to equity fell to $22 million from $98 million a year earlier, while net debt rose to $1.534 billion, or 2.3 times adjusted EBITDA. The company’s full-year cash-conversion and leverage aims therefore depend on a stronger second half. (Convatec)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
ConvaTec Group Financial Performance
Revenues and expenses
ConvaTec Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ConvaTec Group
AllEURUSDGBP
Fund name | Fund size | £CTEC weighting |
|---|---|---|
iShares STOXX Europe Mid 200€EXSD | €610M | 0.34% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.33% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.33% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 0.31% |
iShares Core FTSE 100£ISF | £17B | 0.19% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.